Related Experiment Videos
Home blood glucose monitoring, glycaemic control and diabetic complications
Insights
Home blood glucose monitoring (HBGM) improved glycemic control in diabetic patients. While not statistically significant, HBGM showed a trend towards reduced neuropathy and platelet aggregation compared to standard care.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Clinical Research
Background:
- Diabetic complications and metabolic control are critical health concerns.
- Home blood glucose monitoring (HBGM) is a potential tool for managing diabetes.
Purpose of the Study:
- To evaluate the impact of HBGM on diabetic complications and metabolic control.
- To compare outcomes between patients in an HBGM program and a control group.
Main Methods:
- A 6-month prospective study involving 40 patients in the National Home Blood Glucose Monitoring (HBGM) Programme.
- Comparison with a control group of 18 diabetic patients not on HBGM.
- Assessment of clinical progress, blood glucose, glycosylated hemoglobin, and platelet aggregation.
Main Results:
- Patients on HBGM showed significant improvements in blood glucose (135±8 to 118±5 mg/dl) and HbA1c (10.3±0.4% to 9.3±0.3%).
- The HBGM group had one case of neuropathy deterioration versus three in the control group.
- Control group experienced increased platelet aggregation (30±4% to 37±5%), while the HBGM group showed no change.
Conclusions:
- A six-month HBGM program can lead to improved glycemic control.
- HBGM may be associated with a trend towards decreased deterioration in diabetic neuropathy and platelet aggregability.
- Further research with larger sample sizes is warranted to confirm these findings.
Abstract:
The aim of this study was to evaluate the effect of home blood glucose monitoring on diabetic complications and metabolic control. Forty Chinese and Indian patients participated in the Diabetic Society of Singapore National Home Blood Glucose Monitoring (HBGM) Programme. The clinical progress, the blood glucose and glycosylated haemoglobin concentrations, and the platelet aggregation of the aforementioned patients were studied over a 6-month period; the results were compared with those from a matched, albeit smaller, control group of 18 diabetic patients who were on treatment but not in the HBGM programme. At the end of the six month period, three patients in the control group showed clinical deterioration of peripheral neuropathy in contrast to one patient on HBGM. Due to the small number of patients, the difference in the findings was not statistically significant. Patients on HBGM demonstrated significant improvement in mean grouped blood glucose profile values, 135 +/- 8 to 118 +/- 5 mg/dl, p less than 0.01, and glycosylated haemoglobin levels, 10.3 +/- 0.4 to 9.3 +/- 0.3%, p less than 0.01. The platelet aggregability was unchanged. In contrast, patients in the control group developed a significant increase in platelet aggregation (30 +/- 4% to 37 +/- 5%, p less than 0.05), although the blood glucose and glycosylated haemoglobin concentrations were not significantly altered. This study demonstrated that patients on a six-month HBGM programme were able to achieve improved glycaemic control associated with a trend towards decreased deterioration of diabetic neuropathy and platelet aggregability.